NFE2L2 and chronic myelogenous leukemia, BCR-ABL1 positive: In summary, due to the function and overexpression of Nrf2 in the various types of leukemia and cancer, inhibition of this transcription factor alone or in combination with other cancer therapies such as immunotherapy or chemotherapy can be considered a novel promising therapeutic target; for example, combining therapy of CML patients with Nrf2-siRNA and imatinib enhanced the rate of apoptosis and reduced imatinib resistance [177].